Curi Bio is proud to participate in the 27th NIH Tissue Chip Consortium Meeting & C-Path Public Workshop at the National Cancer Institute. We’ll be in the DC area from Thursday through Saturday, connecting the dots between our mission, providing human data for next-generation medicines, and the critical regulatory frameworks being established by the NIH and C-Path’s Predictive Safety Testing Consortium.
Curi Bio in Action
Our CEO, Nicholas Geisse, will be a featured speaker at the event! He will be speaking on Day 1 (March 5). Nicholas will be presenting on Curi Bio’s BoNT (Botulinum Neurotoxin) assay, showcasing how our 3D Neuromuscular Junction (NMJ) models are advancing functional, human-relevant safety and efficacy testing.
Our CBO, Elliot Fisher, will also be attending and ready to discuss how our 3D ecosystems and workflow are helping partners reduce preclinical risk to make data-driven "Go/No-Go" decisions sooner, maximizing the impact of your R&D investment.
What’s on the Agenda
Day 1 (March 5): Defining "Context of Use" and evidentiary standards, essential steps for making Microphysiological Systems (MPS) a regulatory standard.
Day 2 (March 6): The integration of In-Silico NAMs and tissue chips, the powerful synergy that is reshaping the industry.
Request a Meeting at 27th NIH Tissue Chip Consortium Meeting
🤝 Let's Connect! Please fill out the form below to request a meeting with Nick and/or Elliot.